You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Reply to Mouliou et al
  1. Charles Reynard1,2,
  2. Joy A Allen3,4,
  3. Bethany Shinkins5,
  4. Graham Prestwich6,
  5. Johnathan Goves2,
  6. Kerrie Davies7,
  7. Richard Body2,8
  1. 1 Emergency Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
  2. 2 Division of Cardiovascular Sciences, University of Manchester, Manchester, UK
  3. 3 NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, School of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
  4. 4 NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
  5. 5 Academic Unit of Health Economics, University of Leeds, Leeds, UK
  6. 6 Patient and Public Involvement, Yorkshire and Humber Academic Health Science Networks, Leeds, UK
  7. 7 Healthcare Associated Infections Research Group, University of Leeds, Leeds, UK
  8. 8 Emergency Department, Manchester University NHS Foundation Trust, Manchester, UK
  1. Correspondence to Dr Charles Reynard, Emergency Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; charlie.reynard{at}nhs.net

https://doi.org/10.1136/emermed-2021-212293

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dear Editor,

    We read the response by Mouliou et al to our article entitled ‘COVID-19 Rapid diagnostics: practice review’1 with interest. The authors of the response note that we have labelled PCR and nucleic acid tests as ‘molecular’ and state that lateral flow antigen testing devices should also be given that label. However, we would encourage readers to read the original manuscript, in which we have articulated the difference between molecular and antigen assays.

    The authors were concerned that we were equating ‘rapid diagnostics tests’ in the introduction section with antigen tests We indeed pointed out that a limitation of reverse transcriptase PCR assays is their …

    View Full Text

    Footnotes

    • Handling editor Ellen J Weber

    • Twitter @richardbody

    • Contributors RB and CR drafted the letter. All authors commented and signed off on the reply.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles